Loading organizations...
BioBAY operates as a comprehensive scientific and technological innovation platform dedicated to fostering the biomedical industry within Suzhou Industrial Park. It provides integrated infrastructure and support services, focusing on the development and commercialization of new drugs, high-end medical devices, and biotechnology innovations. The park serves as a critical hub for research, development, and industrialization, aiming to accelerate advancements across these core life science sectors.
Established by the Suzhou Industrial Park in 2007, BioBAY originated from an insight into the growing global demand for robust biomedical innovation ecosystems. Its founders recognized the strategic importance of creating a centralized, state-of-the-art environment to attract leading scientists and entrepreneurial ventures, thereby consolidating resources and expertise to drive significant breakthroughs in life sciences. This foundational vision aimed to cultivate a vibrant, collaborative community.
The platform primarily serves biotechnology and pharmaceutical companies, as well as research institutions engaged in cutting-edge biomedical fields. BioBAY's long-term vision is to establish itself as a leading global biotechnology megahub, providing an optimal environment for emerging companies to grow and contributing significantly to global health advancements through continuous innovation and industrial development.
BioBAY has 1 tracked investment across 1 company. The latest tracked deal is $38.0M Series A in CMAB BioPharm in January 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 2, 2018 | CMAB BioPharm | $38.0M Series A | Biobay, Mengjiao Jiang | I Bridge Capital |